Antibiotic resistance is one of the major challenges facing healthcare systems today. As some bacteria develop mechanisms that reduce the effectiveness of certain treatments, having access to different therapeutic alternatives is becoming increasingly important.
According to the World Health Organization, approximately 1 in 6 laboratory-confirmed bacterial infections in 2023 was resistant to antibiotics.
However, this does not mean that traditional antibiotics are no longer effective. It means that treatment selection should consider the microorganism involved, the type of infection, antimicrobial susceptibility, and local resistance patterns.
What Does Antibiotic Resistance Mean?
We can think of an antibiotic as a key.
For years, that key may work effectively against certain bacteria. However, some bacteria can develop mechanisms that allow them to survive exposure to the medication.
For this reason, addressing antibiotic resistance is not simply about using broader-spectrum medications. It is about selecting the appropriate antibiotic for each situation and using it responsibly.
What Role Do Cephalosporins Play?
Cephalosporins are a broad family of beta-lac tam antibiotics. There are different molecules and generations, each with its own characteristics and spectrum of activity.
They should not be considered an automatic replacement for amoxicillin.
Amoxicillin remains a first-line treatment in several clinical situations. However, certain cephalosporins are also used as therapeutic alternatives in specific scenarios, depending on the diagnosis, susceptibility patterns, allergies, and clinical recommendations.
Therefore, the question should not be:
Amoxicillin or cephalosporins?
But rather:
What is the appropriate option for each clinical situation?
What Does This Mean for the Pharmaceutical Industry?
Antimicrobial resistance also represents a challenge for pharmaceutical companies, distributors, and importers.
For a pharmaceutical company, having access to different antibiotic options can help build a broader portfolio that is better prepared to meet the needs of its market.
However, this must be supported by quality, technical expertise, regulatory documentation, and responsible antimicrobial use.
Cephalosporins at Wexford Laboratories
At Wexford Laboratories, we offer different cephalosporins for third-party pharmaceutical manufacturing.
Our available options include:
Capsules and oral suspensions: Cefadroxil, Cephalexin, and Cefixime.
Powders for solution for injection: Cefazolin, Cefepime, Cefotaxime, and Ceftriaxone.
In addition to third-party manufacturing, we support our clients with documentation for registration processes, samples for analysis and evaluation, and regulatory and commercial support.
Our cephalosporin line is manufactured in dedicated facilities separate from penicillin production as part of our cross-contamination control measures.
Looking to Expand Your Antibiotic Portfolio?
Antibiotic resistance makes access to appropriate therapeutic alternatives increasingly important, while responsible use remains essential.
If you are considering adding cephalosporins to your portfolio, Wexford Laboratories can help you explore the available options and develop pharmaceutical products under your own brand.
Wexford Laboratories
Pharmaceutical Excellence for Third Parties.
